Cross-source identity
National Provider Identifier 1194780114 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1194780114 | Registry identity — dermatologist, taxonomy 207N00000X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1194780114 | 111 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1194780114 | 120 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity 2193140c… | Canonical resolved node · 4 identifier(s) · 5 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,200 | 2 |
| Food and Beverage | $3,033 | 106 |
| Travel and Lodging | $1,441 | 3 |
| Manufacturer | Amount | Records |
|---|---|---|
| Amgen Inc. | $6,678 | 26 |
| Novartis Pharmaceuticals Corporation | $604 | 22 |
| Lilly Usa, Llc | $270 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Farxiga(Dapagliflozin Propanediol) | 186 | $246,186 |
| Mounjaro(Tirzepatide) | 126 | $159,814 |
| Jardiance(Empagliflozin) | 99 | $138,357 |
| Tresiba Flextouch U-200(Insulin Degludec) | 128 | $114,870 |
| Ozempic(Semaglutide) | 71 | $99,480 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Novartis Pharmaceuticals Corporation (NJ) | cms_open_payments |
| ← pays | Novo Nordisk Inc (NJ) | cms_open_payments |
| ← pays | Rgh Enterprises Llc (OH) | cms_open_payments |
| ← pays | Abbvie Inc. (IL) | cms_open_payments |
| ← pays | Astrazeneca Pharmaceuticals Lp (DE) | cms_open_payments |
| 15 |
| Averitas Pharma Inc. | $231 | 18 |
| Medtronic, Inc. | $194 | 4 |